Safety of topiramate for treating migraines

Bibliography

• Silberstein SD, Ben-Menachem E, Shank RP, Wiegand F. Topiramate in monotherapy in epilepsy and migraine prevention. Clin Ther 2005;27:157-65
   Google Scholar
• Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 2001;41(10):968-75
   PubMed Web of Science ®Google Scholar
• Hershey AD, Powers SW, Coffey CS, et al. Childhood and Adolescent Migraine Prevention (CHAMP) study: a double-blinded, placebo-controlled, comparative effectiveness study of amitriptyline, topiramate, and placebo in the prevention of childhood and adolescent migraine. Headache 2013;53(5):799-816
   PubMed Web of Science ®Google Scholar
• Deaton TL, Mauro LS. Topiramate for migraine prophylaxis in pediatric patients. Ann Pharmacother 2014;48(5):638-43
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Ben-Menachem E, Shank RP, Wiegand F. Topiramate monotherapy in epilepsy and migraine prevention. Clin Ther 2005;27(2):154-65
   PubMed Web of Science ®Google Scholar
• Marmura MJ, Hopkins M, Andrel J, et al. Electronic medical records as a research tool: evaluating topiramate use at a headache center. Headache 2010;50(5):769-78
   PubMed Web of Science ®Google Scholar
• Shank RP, Gardocki JF, Vaught JL, et al. Topiramate: preclinical evaluation of structurally novel anticonvulsant. Epilepsia 1994;35(2):450-60
   PubMed Web of Science ®Google Scholar
• Guerrini R. Epilepsy in children. Lancet 2006;367(9509):499-524
   PubMed Web of Science ®Google Scholar
• Sachdeo RC, Glauser TA, Ritter F, et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology 1999;52(9):1882-7
   PubMed Web of Science ®Google Scholar
• Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377(9774):1341-52
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007;47(2):170-80
   PubMed Web of Science ®Google Scholar
• Domingues RB, Kuster GW, Aquino CC. Treatment of trigeminal neuralgia with low doses of topiramate. Arq Neuropsiquiatr 2007;65(3B):792-4
   PubMed Web of Science ®Google Scholar
• Leone M, Dodick D, Rigamonti A, et al. Topiramate in cluster headache prophylaxis: an open trial. Cephalalgia 2003;23(10):1001-2
   PubMed Web of Science ®Google Scholar
• Brighina F, Palermo A, Cosentino G, Fierro B. Prophylaxis of hemicrania continua: two new cases effectively treated with topiramate. Headache 2007;47(3):441-3
   PubMed Web of Science ®Google Scholar
• Celebisoy N, Gokcay F, Sirin H, Akyurekli O. Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study. Acta Neurol Scand 2007;116(5):322-7
   PubMed Web of Science ®Google Scholar
• Shank RP, Gardocki JF, Streeter AJ, Maryanoff B. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000;41(S1):S3-9
   PubMedGoogle Scholar
• Anderson RE, Chiu P, Woodbury DM. Mechanisms of tolerance to the anticonvulsant effects of acetazolamide in mice: relation to the activity and amount of carbonic anhydrase in brain. Epilepsia 1989;30(2):208-16
   PubMed Web of Science ®Google Scholar
• Ayata C, Jin H, Kudo C, et al. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 2006;59(4):652-61
   PubMed Web of Science ®Google Scholar
• Cosentino G, Fierro B, Vigneri S, et al. Impaired glutamatergic neurotransmission in migraine with aura? Evidence by an input-output curves transcranial magnetic stimulation study. Headache 2011;51(5):726-33
   PubMed Web of Science ®Google Scholar
• Rosenfeld WE. Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin Ther 1997;19(6):1294-308
   PubMed Web of Science ®Google Scholar
• Johannessen SI. Pharmacokinetics and interaction profile of topiramate: review and comparison with other newer antiepileptic drugs. Epilepsia 1997;38(Suppl 1):S18-23
   PubMed Web of Science ®Google Scholar
• Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004;291(8):965-73
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Neto W, Schmitt J, Jacobs D. Topiramate in the prevention of migraine headache: a randomized, double-blind, placebo-controlled, multiple-dose study. For the MIGR-001 Study Group. Arch Neurol 2004;61:490-5
   PubMed Web of Science ®Google Scholar
• Leppik IE. Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure 2004;13(Suppl 1):S5-9
   PubMed Web of Science ®Google Scholar
• Mcmurdo ME, Hutchison GL, Lindsay G. Taste disturbance with acetazolamide. Lancet 1990;336(8724):1190-1
   PubMed Web of Science ®Google Scholar
• Borron SW, Woolard R, Watts S. Fatal heat stroke associated with topiramate therapy. Am J Emerg Med 2013;31(12):1720-6
   PubMedGoogle Scholar
• Danielsson BR, Lansdell K, Patmore L, Tomson T. Effects of the antiepileptic drugs lamotrigine, topiramate and gabapentin on hERG potassium currents. Epilepsy Res 2005;63(1):17-25
   PubMed Web of Science ®Google Scholar
• Mirza NS, Alfirevic A, Jorgensen A, et al. Metabolic acidosis with topiramate and zonisamide: an assessment of its severity and predictors. Pharmacogenet Genomics 2011;21(5):297-302
   PubMed Web of Science ®Google Scholar
• Dell’orto VG, Belotti EA, Goeggel-Simonetti B, et al. Metabolic disturbances and renal stone promotion on treatment with topiramate: a systematic review. Br J Clin Pharmacol 2014;77(6):958-64
   PubMed Web of Science ®Google Scholar
• Belotti EA, Taddeo I, Ragazzi M, et al. Chronic impact of topiramate on acid-base balance and potassium in childhood. Eur J Paediatr Neurol 2010;14(5):445-8
   Web of Science ®Google Scholar
• Silberstein SD. Control of topiramate-induced paresthesias with supplemental potassium (Letter). Headache 2002;42-85
   Google Scholar
• Brandes JL. Practical use of topiramate for migraine prevention. Headache 2005;45(Suppl 1):S66-73
   PubMedGoogle Scholar
• Takeoka M, Riviello JJ Jr, Pfeifer H, Thiele EA. Concomitant treatment with topiramate and ketogenic diet in pediatric epilepsy. Epilepsia 2002;43(9):1072-5
   PubMed Web of Science ®Google Scholar
• Caudarella R, Vescini F. Urinary citrate and renal stone disease: the preventive role of alkali citrate treatment. Arch Ital Urol Androl 2009;81(3):182-7
   PubMedGoogle Scholar
• Ho JD, Keller JJ, Tsai CY, et al. Topiramate use and the risk of glaucoma development: a population-based follow-up study. Am J Ophthalmol 2013;155(2):336-41
   PubMed Web of Science ®Google Scholar
• Quagliato LB, Barella K, Abreu Neto JM, Quagliato EM. Topiramate-associated acute, bilateral, angle-closure glaucoma: case report. Arq Bras Oftalmol 2013;76(1):48-9
   PubMed Web of Science ®Google Scholar
• Van IC, Mavrakanas N, Schutz JS, Shaarawy T. Topiramate-induced acute bilateral angle closure and myopia: pathophysiology and treatment controversies. Eur J Ophthalmol 2011;21(4):404-9
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA 2014;311(18):1901-11
   PubMed Web of Science ®Google Scholar
• Arif H, Buchsbaum R, Weintraub D, et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 2007;68(20):1701-9
   PubMed Web of Science ®Google Scholar
• Lee S, Sziklas V, Andermann F, et al. The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia 2003;44(3):339-47
   PubMed Web of Science ®Google Scholar
• Kanner AM. Depression in epilepsy: a frequently neglected multifaceted disorder. Epilepsy Behav 2003;4(Suppl 4):11-19
   PubMedGoogle Scholar
• Romigi A, Cervellino A, Marciani MG, et al. Cognitive and psychiatric effects of topiramate monotherapy in migraine treatment: an open study. Eur J Neurol 2008;15(2):190-5
   PubMed Web of Science ®Google Scholar
• Wheeler SD. Donepezil treatment of topiramate-related cognitive dysfunction. Headache 2006;46(2):332-5
   PubMed Web of Science ®Google Scholar
• Evans RW. Reversible palinopsia and the Alice in Wonderland syndrome associated with topiramate use in migraineurs. Headache 2006;46(5):815-18
   PubMed Web of Science ®Google Scholar
• Fontenelle LF. Topiramate-induced palinopsia. J Neuropsychiatry Clin Neurosci 2008;20(2):249-50
   PubMed Web of Science ®Google Scholar
• Sierra-Hidalgo F, de Pablo-Fernandez E. Palinopsia induced by topiramate and zonisamide in a patient with migraine. Clin Neuropharmacol 2013;36(2):63-4
   PubMed Web of Science ®Google Scholar
• Hayashi R, Shimizu S, Watanabe R, et al. Palinopsia and perilesional hyperperfusion following subcortical hemorrhage. Acta Neurol Scand 2002;105(3):228-31
   PubMed Web of Science ®Google Scholar
• Connor GS. A double-blind placebo-controlled trial of topiramate treatment for essential tremor. Neurology 2002;59(1):132-4
   PubMed Web of Science ®Google Scholar
• Alonso-Navarro H, Jimenez-Jimenez FJ. Reversible tremor, myoclonus, and fasciculations associated with topiramate use for migraine. Clin Neuropharmacol 2006;29(3):157-9
   PubMed Web of Science ®Google Scholar
• Oulis P, Potagas C, Masdrakis VG, et al. Reversible tremor and myoclonus associated with topiramate-fluvoxamine coadministration. Clin Neuropharmacol 2008;31(6):366-7
   PubMed Web of Science ®Google Scholar
• Mantoan L, Walker M. Treatment options in juvenile myoclonic epilepsy. Curr Treat Options Neurol 2011;13(4):355-70
   PubMed Web of Science ®Google Scholar
• Hunt S, Russell A, Smithson WH, et al. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 2008;71(4):272-6
   PubMed Web of Science ®Google Scholar
• Margulis AV, Mitchell AA, Gilboa SM, et al. Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol 2012;207(5):405-7
   PubMedGoogle Scholar
• Ohman I, Vitols S, Luef G, et al. Topiramate kinetics during delivery, lactation, and in the neonate: preliminary observations. Epilepsia 2002;43(10):1157-60
   PubMed Web of Science ®Google Scholar
• Johannessen SI, Landmark CJ. Antiepileptic drug interactions - principles and clinical implications. Curr Neuropharmacol 2010;8(3):254-67
   PubMed Web of Science ®Google Scholar
• Hamer HM, Knake S, Schomburg U, Rosenow F. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology 2000;54(1):230-2
   PubMed Web of Science ®Google Scholar
• Holroyd KA, Penzien DB, Coordingley GE. Propranolol in the management of recurrent migraine: a meta-analytic review. Headache 1991;31:333-40
   PubMed Web of Science ®Google Scholar
• Stellar S, Ahrens SP, Meibohm AR, Reines SA. Migraine prevention with timolol: a double-blind crossover study. JAMA 1984;252(18):2576-80
   PubMed Web of Science ®Google Scholar
• Freitag FG, Collins SD, Carlson HA, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002;58(11):1652-9
   PubMed Web of Science ®Google Scholar
• Schoenen J, Vandersmissen B, Jeangette S, et al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology 2013;80(8):697-704
   PubMed Web of Science ®Google Scholar
• Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006;26(6):742-6
   PubMed Web of Science ®Google Scholar
• Dodick DW, Turkel CC, Degryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50(6):921-36
   PubMed Web of Science ®Google Scholar
• Aurora SK, Gawel M, Brandes JL, et al. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache 2007;47(4):486-99
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Marmura MJ. Essential neuropharmacology: the prescriber’s guide. In: Essential neuropharmacology: the prescriber’s guide. Cambridge University press, New York; 2010
   Google Scholar
• Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group. Neurology 1996;46(6):1684-90
   PubMed Web of Science ®Google Scholar
• Lo YL, Lum SY, Fook-Chong S, Siow HC. A pilot study of topiramate dosages for migraine prophylaxis in an Asian population. J Headache Pain 2010;11(2):175-8
   PubMed Web of Science ®Google Scholar
• Cosentino G, Paladino P, Maccora S, et al. Efficacy and safety of topiramate in migraine prophylaxis: an open controlled randomized study comparing Sincronil and topamax formulations. Panminerva Med 2013;55(3):303-7
   PubMed Web of Science ®Google Scholar
• Sachdev A, Marmura MJ. Metabolic syndrome and migraine. Front Neurol 2012;31:61
   Google Scholar
• Silberstein SD, Diamond S, Loder E, et al. Prevalence of migraine sufferers who are candidates for preventive therapy: results from the American migraine study (AMPP) study [abstract]. Headache 2005;45:770-1
   Web of Science ®Google Scholar
• Young WB, Silberstein SD, Nahas SJ, et al. Jefferson headache manual. In: Jefferson, editor. Headache manual. Demos Medical, New York; 2010
   Google Scholar